Zacks Investment Research Upgrades H. Lundbeck A/S- (HLUYY) to “Strong-Buy”

H. Lundbeck A/S- (OTCMKTS:HLUYY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report issued on Saturday. The brokerage currently has a $58.00 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 11.56% from the stock’s previous close.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) traded up $1.17 during mid-day trading on Friday, hitting $51.99. The stock had a trading volume of 2,369 shares, compared to its average volume of 4,741. The firm has a market capitalization of $10,110.00, a P/E ratio of 26.94, a PEG ratio of 1.32 and a beta of 0.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.13 and a current ratio of 1.36. H. Lundbeck A/S- has a 1-year low of $40.70 and a 1-year high of $66.67.

H. Lundbeck A/S- (OTCMKTS:HLUYY) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.73 earnings per share (EPS) for the quarter. H. Lundbeck A/S- had a return on equity of 30.48% and a net margin of 15.07%. sell-side analysts forecast that H. Lundbeck A/S- will post 2.44 earnings per share for the current year.

WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/zacks-investment-research-upgrades-h-lundbeck-a-s-hluyy-to-strong-buy.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply